Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody ...
SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) ...
Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback